Courier Capital LLC raised its holdings in shares of ImmunityBio, Inc. (NASDAQ:IBRX – Free Report) by 100.0% during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 112,000 shares of the company’s stock after purchasing an additional 56,000 shares during the period. Courier Capital LLC’s holdings in ImmunityBio were worth $1,057,000 at the end of the most recent quarter.
A number of other institutional investors and hedge funds have also modified their holdings of the business. Markowski Investments purchased a new position in shares of ImmunityBio in the second quarter worth $29,000. GAMMA Investing LLC lifted its holdings in shares of ImmunityBio by 262.2% during the third quarter. GAMMA Investing LLC now owns 3,807 shares of the company’s stock valued at $36,000 after purchasing an additional 2,756 shares in the last quarter. Hollencrest Capital Management purchased a new stake in shares of ImmunityBio during the second quarter valued at $44,000. Western Wealth Management LLC purchased a new stake in shares of ImmunityBio during the first quarter valued at $44,000. Finally, Geneos Wealth Management Inc. increased its holdings in ImmunityBio by 579.3% in the 1st quarter. Geneos Wealth Management Inc. now owns 5,754 shares of the company’s stock worth $44,000 after buying an additional 4,907 shares in the last quarter. Institutional investors own 8.58% of the company’s stock.
ImmunityBio Stock Down 3.2%
IBRX traded down $0.32 during mid-day trading on Tuesday, reaching $9.80. 11,534,240 shares of the company traded hands, compared to its average volume of 20,568,516. The company’s fifty day moving average price is $8.37 and its 200-day moving average price is $7.91. The stock has a market capitalization of $10.39 billion, a P/E ratio of -10.10 and a beta of 0.02. ImmunityBio, Inc. has a 52-week low of $1.95 and a 52-week high of $12.43.
Analyst Ratings Changes
A number of brokerages have weighed in on IBRX. Weiss Ratings reissued a “sell (d-)” rating on shares of ImmunityBio in a research report on Tuesday, October 6th. Jefferies Financial Group raised shares of ImmunityBio to a “strong-buy” rating in a report on Friday, September 25th. One equities research analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat.com, ImmunityBio has a consensus rating of “Moderate Buy” and an average price target of $14.20.
View Our Latest Stock Analysis on ImmunityBio
Insider Transactions at ImmunityBio
In other ImmunityBio news, Director Cheryl Cohen sold 81,056 shares of the stock in a transaction dated Friday, October 2nd. The stock was sold at an average price of $10.50, for a total value of $851,088.00. Following the transaction, the director owned 100,309 shares of the company’s stock, valued at approximately $1,053,244.50. This represents a 44.69% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Barry Simon sold 25,000 shares of the firm’s stock in a transaction dated Monday, October 5th. The stock was sold at an average price of $10.75, for a total value of $268,750.00. Following the completion of the transaction, the director directly owned 2,777,788 shares in the company, valued at $29,861,221. The trade was a 0.89% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 66.10% of the stock is currently owned by corporate insiders.
ImmunityBio Company Profile
ImmunityBio, Inc is a biotechnology company focused on developing and commercializing immunotherapies designed to activate and strengthen the body’s immune system against cancer and infectious diseases. The company combines cytokine-based therapies, vaccines, cellular therapies and other immune-modulating technologies in an effort to create durable treatment responses.
Its lead product, ANKTIVA (nogapendekin alfa inbakicept-pmln), is an interleukin-15 receptor agonist immune stimulator.
Read More
- Five stocks we like better than ImmunityBio
- A Chinese Rival Just Spooked Memory Stocks—How Worried Should Micron Investors Be?
- Could T-Mobile’s Satellite Competition Fears Create a Buying Opportunity?
- Surgical Precision, Sustainable Returns: Johnson & Johnson Secures Its Cash Flow Runway
- Tesla’s Robotaxi Lands in Paris—But Europe’s Real Fight Is Over Cheap EVs
Want to see what other hedge funds are holding IBRX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for ImmunityBio, Inc. (NASDAQ:IBRX – Free Report).
Receive News & Ratings for ImmunityBio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ImmunityBio and related companies with MarketBeat.com's FREE daily email newsletter.
